What Does CJC-1295 DAC Do?

CJC-1295 DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) that binds to albumin in the bloodstream, extending its half-life to roughly 6 to 8 days. In research models, it stimulates the pituitary to release growth hormone and raises IGF-1 levels, creating a sustained elevation rather than a short pulse. CJC-1295 DAC is not FDA-approved for human use, and all dosing information comes from animal studies and limited early human trials.

If you have ever typed what does cjc 1295 with dac do into a search bar, you are not alone. This is one of the most common questions about the peptide, and the short answer is that it keeps growth hormone release elevated for days instead of minutes.

How CJC-1295 DAC Works in the Body

CJC-1295 is a modified version of GRF (1-29), the active fragment of GHRH. The "DAC" stands for drug affinity complex, a maleimide group that covalently binds the peptide to serum albumin after injection.

That albumin binding is the key difference. It protects the peptide from rapid enzymatic breakdown and slows clearance, which is why a single injection can influence growth hormone for several days.

• Binds GHRH receptors on pituitary somatotroph cells.
• Increases growth hormone release and, indirectly, hepatic IGF-1 production.
• Raises baseline GH rather than mimicking the body's natural pulses.
• Extends half-life to roughly 6-8 days in published human data.

Because GH is normally released in pulses, a long-acting analog changes the rhythm of secretion. Some researchers view that as an advantage; others see it as a reason to prefer shorter-acting peptides.

CJC-1295 With DAC vs Without DAC

The comparison what is cjc-1295 with dac vs without dac comes down to one variable: albumin binding. The no-DAC version, often called Mod GRF 1-29, lacks the maleimide group and has a half-life of about 30 minutes.

The sustained elevation from the DAC version also means side effects, if they occur, take longer to clear. That is a practical reason some researchers choose the no-DAC form for tighter control.

Typical Research Dosages

No standardized human dose exists because CJC-1295 is not approved for clinical use. Reported cjc-1295 with dac dosage in research settings usually falls between 1 mg and 2 mg per week, often given as a single injection.

A typical cjc-1295 no dac dosage is 100 mcg per injection, administered one to three times daily, sometimes paired with a GHRP such as ipamorelin.

These numbers come from published animal work, small human trials, and community reports. They are not medical recommendations.

Stacking, Reconstitution, and Storage

CJC-1295 is frequently studied alongside ipamorelin because the two act on different receptors. A GHRH analog plus a ghrelin-receptor agonist can produce a larger GH pulse than either alone in some models.

Many beginners also ask what does bac water do for peptides, and the answer is simple: bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth and lets a reconstituted vial be used over several weeks.

• Reconstitute with bacteriostatic water, not sterile water, for multi-use vials.
• Store lyophilized powder in the freezer, away from light.
• Refrigerate reconstituted peptide at 2-8 degrees Celsius (36-46 degrees Fahrenheit).
• Avoid vigorous shaking, which can degrade the peptide chain.

Side Effects, Safety, and Legal Status

CJC-1295 DAC is a research chemical. It is not approved by the FDA for human use, and it cannot be legally sold as a dietary supplement or prescription drug in the United States.

Reported side effects in small studies and user reports include injection-site reactions, flushing, headache, water retention, fatigue, and a temporary increase in heart rate.

Because of the long half-life, any adverse reaction may persist for days. Elevated IGF-1 over long periods is a theoretical concern, and individuals with hormone-sensitive conditions are generally advised to avoid these compounds.

Anyone considering CJC-1295 should discuss it with a licensed healthcare professional and understand that purity, dosing, and long-term safety data are limited.

Bloodwork monitoring, including IGF-1 and fasting glucose, is often mentioned in research discussions, but no formal monitoring guideline exists for non-approved use.

Key Takeaways

• CJC-1295 DAC is a long-acting GHRH analog that binds albumin and raises growth hormone for days.
• The no-DAC version works for minutes and requires frequent injections.
• Neither form is FDA-approved for human use.
• Reported research doses are not medical advice, and a healthcare professional should be consulted before use.